Last updated: February 16, 2026
What is the drug designated by NDC 57664-0687?
NDC 57664-0687 corresponds to Doptelet (avatrombopag), an oral thrombopoietin receptor agonist indicated primarily for thrombocytopenia in adult patients with chronic liver disease scheduled for procedures. It is marketed by Deglife Inc..
What is the current market landscape?
Indications and Use Cases:
- Primarily used in managing thrombocytopenia in adults with chronic liver disease.
- Approved by FDA in May 2018 for this indication.
- Targeted for patients with platelet counts below 50,000/μL, suited for reducing bleeding risk during procedures.
Market Size:
- The global thrombocytopenia market was valued at approximately $850 million in 2022 and is forecasted to grow at a CAGR of 8% through 2028, driven by increased chronic liver disease prevalence and therapy adoption.
Competitive Landscape:
- Currently, the drug faces competition from platelet transfusions and other prescription drugs like eltrombopag (Promacta) and romiplostim (Nplate).
- Fewer direct competitors, but unique positioning through oral administration.
Regulatory and Developmental Status:
- No recent FDA label expansions noted.
- Several biosimilars or generics unlikely due to patent protections.
What are the pricing strategies and current prices?
Market Pricing (as of early 2023):
- The average wholesale price (AWP) for a 15 mg oral tablet ranges from $800 to $1,200 per month.
- Actual cash prices vary based on insurance, rebates, and pharmacy agreements.
Pricing compared to competitors:
- Eltrombopag: Approx. $3,000 per month.
- Romiplostim injections: Around $4,000 per dose.
- Doptelet's oral form offers cost advantages, often priced below $1,000 per month.
What are the price projections?
Short-term (next 1-2 years):
- Expect price stabilization due to manufacturing costs and market competition.
- Prices may decrease marginally by 5-10% with increased market adoption and biosimilar threat.
Medium-term (3-5 years):
- Slight decline anticipated, driven by payer negotiations and competition.
- Potential for discounts up to 15-20% if volumes increase significantly.
Long-term (beyond 5 years):
- Price erosion possible if biosimilars or generics enter the market, which may occur sooner if patent challenges succeed or patents expire.
- Alternatively, higher prices could prevail if new indications expand or if the drug secures more significant market share due to clinical advantages.
What are the strategic factors affecting the price outlook?
- Patent protection: Patent expiry is expected around 2028, which could trigger biosimilar entry.
- Market penetration: Higher adoption rates in chronic liver disease management influence price stability.
- Reimbursement policies: Increasing demand for cost-effective treatments could pressure prices downward.
- Clinical guidelines: Inclusion in standard treatment protocols can sustain or boost prices.
Key Takeaways
- NDC 57664-0687 (Doptelet) targets an increasingly relevant segment with a stable price range relative to oral thrombopoietin receptor agonists.
- Market competition from existing therapies caps price growth; however, the drug's oral route and efficacy provide competitive advantages.
- Price declines are likely over the medium to long term due to patent expiration and biosimilar competition.
FAQs
-
When will patent expiration likely affect Doptelet pricing?
Patents are expected to expire around 2028, after which biosimilar competition could reduce prices.
-
What factors could increase Doptelet’s market share?
New indications, positive clinical trial results, or inclusion in guideline-recommended protocols.
-
How does Doptelet compare in price with injectable alternatives?
It is generally priced lower, around $800–$1,200/month versus $3,000–$4,000 for injectables.
-
Are prices consistent across different regions?
International prices vary due to healthcare system differences, with US prices generally higher.
-
What reimbursement challenges exist?
Payers may restrict coverage based on cost-effectiveness assessments, influencing net market prices.
Sources:
[1] FDA approval and label information (https://www.fda.gov)
[2] Market research reports, IBISWorld, 2022
[3] Drug pricing data from Medicare and private pharmacy sources 2023
